Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
Fujifilm said on July 8 that its biologics CDMO facility in Holly Springs, North Carolina, has been selected for the FDA’s PreCheck Pilot Program, an initiative aimed at accelerating the launch of new drug manufacturing facilities in the US. The…
To read the full story
Related Article
- Kyowa Kirin Selected for FDA Pilot to Speed US Plant Launch
July 2, 2026
- Fujifilm Launches US$3.2 Billion Biologics Plant in North Carolina
September 26, 2025
- Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
- Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…